QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive results of a Phase IV clinical trial of Aczone? in more than 50 patients with G6PD deficiency that was performed to meet a post-approval commitment requested by the FDA. The purpose of this study was to gather more information about the safety of Aczone, a prescription topical medicine, in treating patients with acne who have certain blood disorders.
Abbott and Kos Pharmaceuticals, Inc. today announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net of cash currently held by Kos. Based in Cranbury, N.J., Kos is a specialty pharmaceutical company that develops and markets proprietary medications for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company has a growing presence in the $20 billion lipid management market.
Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Eli Lilly and Company’s ZYPREXA(R) Zydis(R) (Olanzapine) Orally Disintegrating Tablets, 5mg, 10mg, 15mg and 20mg.
Bayer HealthCare announced today a structural realignment of its global pharmaceutical research and development organization. The company also outlined its future U.S. pharma site plan, and said that New Jersey will be home to its U.S. headquarters for pharmaceuticals. These moves follow Bayer?s acquisition of Schering AG, Germany in June 2006 and are part of the company?s plan to integrate its pharmaceutical operations with those of Schering AG and Berlex Inc. (the U.S. subsidiary of Schering AG).
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the treatment of moderate to severe primary Restless Legs Syndrome (RLS).1 This is an important milestone for pramipexole (Mirapexin? / Sifrol? / Mirapex?), which was already approved throughout the European Union in April 2006 for this second indication.
A new UCLA study has found that physicians discuss cost and aspects of obtaining newly prescribed medications only about one-third of the time during patient/doctor interactions.
Researchers at Johns Hopkins have figured out how one particular protein contributes to long-term memory and helps the brain remember things longer than an hour or two. The findings are reported in two papers in the November 9 issue of Neuron.
American researchers have found that giving a combination of imantanib and a drug that induces cell death was better at inhibiting the growth of Ewing’s sarcoma in mice than either therapy on its own, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.
Researchers in the UK and the United States have found that a drug composed of an antibody carrying a highly toxic anti-cancer agent is well tolerated by patients at much higher doses than have been used before, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.
Acetaminophen 500-milligram caplets made by the Perrigo Co. are being recalled because they could contain metal fragments. The move affects 11 million bottles sold under store brands by Wal-Mart, CVS, Safeway and more than 120 other major retailers. CVS Corp. and SuperValu Inc. have already begun taking out the pills from store shelves.